These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7940927)

  • 1. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine.
    Holt DW; Mueller EA; Kovarik JM; van Bree JB; Kutz K
    Transplant Proc; 1994 Oct; 26(5):2935-9. PubMed ID: 7940927
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of pharmacokinetics between CsA capsules and Sandimmun Neoral in pediatric patients.
    Lin CY; Lee SF
    Transplant Proc; 1994 Oct; 26(5):2973-4. PubMed ID: 7940938
    [No Abstract]   [Full Text] [Related]  

  • 3. Sandimmun neoral pharmacokinetics: impact of the new oral formulation.
    Holt DW; Mueller EA; Kovarik JM; van Bree JB; Richard F; Kutz K
    Transplant Proc; 1995 Feb; 27(1):1434-7. PubMed ID: 7878935
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclosporine pharmacokinetics in renal allograft recipients with diabetes mellitus with Sandimmune and Sandimmune Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Durlik M; Lao M
    Transplant Proc; 1996 Dec; 28(6):3140-1. PubMed ID: 8962217
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced absorption of new oral cyclosporin microemulsion formulation, Neoral, in liver transplant recipients with external biliary diversion.
    Trull AK; Tan KK; Tan L; Alexander GJ; Jamieson NV
    Transplant Proc; 1994 Oct; 26(5):2977-8. PubMed ID: 7940939
    [No Abstract]   [Full Text] [Related]  

  • 7. [Variability of the bioavailability of cyclosporine: benefit of the Neoral formulation].
    Humbert H
    Therapie; 1997; 52(4):353-7. PubMed ID: 9437891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients.
    Cooney GF; Lum BL; Meligeni JA; Dunn SP
    Transplant Proc; 1996 Aug; 28(4):2270-2. PubMed ID: 8769222
    [No Abstract]   [Full Text] [Related]  

  • 9. Preliminary pharmacokinetic evaluation of a new galenical formulation of oral cyclosporine A: Neoral TM.
    Foradori AC; Martínez L; Elberg A; Vaccarezza A; Loveluck A; Pinto C
    Transplant Proc; 1995 Apr; 27(2):1813-4. PubMed ID: 7725515
    [No Abstract]   [Full Text] [Related]  

  • 10. Relative bioavailability of Sandimmune and Sandimmune Neoral in pediatric liver recipients.
    Superina RA; Strong DK; Acal LA; DeLuca E
    Transplant Proc; 1994 Oct; 26(5):2979-80. PubMed ID: 7940940
    [No Abstract]   [Full Text] [Related]  

  • 11. Sandimmun neoral, a new oral formulation of cyclosporin A with improved pharmacokinetic characteristics: safety and tolerability in renal transplant patients.
    Taesch S; Niese D; Mueller EA
    Transplant Proc; 1994 Dec; 26(6):3147-9. PubMed ID: 7998097
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclosporine neoral pharmacokinetics in kidney and heart transplant patients.
    Schiavelli R; Sgrosso JL; Sabbatiello R; Castro C; Ahualli L; Pattin M; Vazquez MC
    Transplant Proc; 1996 Dec; 28(6):3343-4. PubMed ID: 8962299
    [No Abstract]   [Full Text] [Related]  

  • 13. Change of conventional cyclosporine to neoral cyclosporine formulation in long-term liver transplant recipients.
    Diliz HS; Olivera MA; Kershenobich D; Mercado MA; Orozco H
    Transplant Proc; 1996 Dec; 28(6):3348-50. PubMed ID: 8962302
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the pharmacokinetics of cyclosporine Sandimmune with Sandimmune Neoral in stable renal transplant patients.
    Sketris IS; Lawen JG; Beauregard-Zollinger L; Belitsky P; Landsberg D; Givner ML; Keown P
    Transplant Proc; 1994 Oct; 26(5):2961-3. PubMed ID: 7940935
    [No Abstract]   [Full Text] [Related]  

  • 15. Neoral pharmacokinetics in cynomolgus monkeys: relation to efficacy in renal allografting.
    Schuurman HJ; Hengy JC; Ringers J; Vonderscher J; Schuler W; Jonker M
    Transplant Proc; 1996 Dec; 28(6):3142-4. PubMed ID: 8962218
    [No Abstract]   [Full Text] [Related]  

  • 16. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients.
    Kahan BD; Dunn J; Fitts C; Van Buren D; Wombolt D; Pollak R; Carson R; Alexander JW; Chang C; Choc M
    Transplant Proc; 1994 Oct; 26(5):2940-3. PubMed ID: 7940928
    [No Abstract]   [Full Text] [Related]  

  • 17. Cyclosporine pharmacokinetics in stable renal transplant patients: effect of formulation Sandimmun versus Consupren versus Neoral.
    Masri MA; Barbari A; Stephan A; Kamel G; Frem G; Younan F; Rizk S; Moubarak R; Karam A
    Transplant Proc; 1996 Jun; 28(3):1318-20. PubMed ID: 8658676
    [No Abstract]   [Full Text] [Related]  

  • 18. Experience with clinical use of Sandimmun Neoral in renal transplant patients.
    Min ZL; Zhao M; Zhu YH; Qi J; Wang LM; Wang YW
    Transplant Proc; 1996 Jun; 28(3):1356-7. PubMed ID: 8658692
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
    Müller RH; Runge S; Ravelli V; Mehnert W; Thünemann AF; Souto EB
    Int J Pharm; 2006 Jul; 317(1):82-9. PubMed ID: 16580159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J
    Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.